JNJ-17216498

DB17087InvestigationalSmall molecule

JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.

Mechanism: Pharmacologically active on Histamine H3 receptor
Curator reviewed
Code names: JNJ-17216498

Resolves to

Compound

Targets

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with JNJ-17216498, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.